Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and represents a significant health care issue. The diagnosis and management of AF uses a significant proportion of the health care budget and is responsible for substantial morbidity and mortality. Restoration and maintenance of sinus rhythm is still an important treatment option for symptomatic AF. Anti-arrhythmic drugs (AADs) have had inconsistent results for the prevention of recurrent AF and have been hampered by significant adverse effects. Catheter ablation has rapidly evolved and is fast becoming an alternative for AF prevention. Although multiple treatment options exist, no single modality is effective for all patients. This review outlines best current practice for AF prevention and future perspectives, focusing on new and promising developments in antiarrhythmic drug therapy, strategies for ablation therapy, and forms of hybrid therapy that may offer improved outcomes in selected patients.
Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA . 2001; 285(18):2370-2375.
2.
Wang TJ, Larson MG, Levy D., et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study . Circulation. 2003; 107(23):2920-2925.
3.
Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H., Kannel WB, Levy D.Impact of atrial fibrillation on the risk of death: the Framingham Heart Study . Circulation. 1998;98(10): 946-952.
4.
Miyasaka Y., Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119-125.
5.
Stewart S., Murphy NF, Walker A., McGuire A., McMurray JJCost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart. 2004;90(3):286-292.
6.
Coyne KS, Paramore C., Grandy S., Mercader M., Reynolds M., Zimetbaum P.Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health. 2006;9(5): 348-356.
7.
Hohnloser SH , Kuck KH, Lilienthal J.Rhythm or rate control in atrial fibrillation-Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet. 2000 ;356(9244): 1789-1794.
8.
Van GI, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med . 2002;347(23):1834-1840.
9.
Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002 ;347(23):1825-1833.
10.
Arya A., Silberbauer J., Teichman SL, Milner P., Sulke N., Camm AJA preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology. Europace.2009;11(4):458-464.
11.
Ezekowitz M.Budiodarone reduces AF burden in patients with pacemakers. Presented at: Heart Rhythm2009 ; May 13-16, 2009; Boston, MA.
12.
Gautier P., Serre M., Cosnier-Pucheu S., et al. In vivo and in vitro antiarrhythmic effects of SSR149744C in animal models of atrial fibrillation and ventricular arrhythmias. J Cardiovasc Pharmacol. 2005;45(2):125-135.
13.
Kowey PR, Aliot EM, Capucci A., et al. Placebo controlled double-blind dose-ranging study of the efficacy and safety of SSR149744C in patients with recent atrial fibrillation/flutter (Abstract). Heart Rhythm Soc. 2007;4(Supplement):5S.
14.
Savelieva I. , Camm AJAnti-arrhythmic drug therapy for atrial fibrillation:current anti-arrhythmic drugs, investigational agents and innovative approaches. Europace. 2009;10:647-665.
15.
Kowey PR, Dorian P., Mitchell LB, Pratt CM, Roy D., Schwartz PJ, et al. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol.2009;2(6):652-659.
16.
Shiroshita-Takeshita A., Ford J., Madge D., Pinnock R., Nattel S.Electrophysiological and atrial antiarrhythmic effects of a novel IKur/Kv1.5 blocker in dogs with atrial tachycardia remodeling (Abstract). Heart Rhythm Soc . 2006;3:S183.
17.
Lofberg L., Jacobson I., Carlsson L.Electrophysiological and antiarrhythmic effects of the novel antiarrhythmic agent AZD7009: a comparison with azimilide and AVE0118 in the acutely dilated right atrium of the rabbit in vitro. Europace. 2006;8(7):549-557.
18.
Blaauw Y., Gogelein H., Tieleman RG, van HA, Schotten U., Allessie MA"Early’’ class III drugs for the treatment of atrial fibrillation: efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat . Circulation. 2004;110(13):1717-1724.
19.
Antzelevitch C., Belardinelli L., Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties . Circulation. 2004;110(8):904-910.
20.
Scirica BM, Morrow DA, Hod H., et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation. 2007;116(15):1647-1652.
21.
Camm AJ, Savelieva I.Advances in antiarrhythmic drug treatment of atrial fibrillation: where do we stand now? Heart Rhythm. 2004;1(2):244-246.
22.
Cha TJ, Ehrlich JR, Chartier D., Qi XY, Xiao L., Nattel S.Kir3-based inward rectifier potassium current: potential role in atrial tachycardia remodeling effects on atrial repolarization and arrhythmias. Circulation. 2006;113(14):1730-1737.
23.
Borchard R. , Van Bracht M., Wickenbrock I., Prull MW, Pott L., Trappe HJInhibition of the muscarinic potassium current by KB130015, a new anti-arrhythmic agent to treat atrial fibrillation. Med Klin. 2005;100(11):697-703.
24.
Hashimoto N. , Yamashita T., Tsuruzoe N.Characterization of in vivo and in vitro electrophysiological and antiarrhythmic effects of a novel IKACh blocker, NIP-151: a comparison with an IKrblocker dofetilide. J Cardiovasc Pharmacol. 2008;51(2):162-169.
25.
Schlotthauer K., Bers DMSarcoplasmic reticulum Ca(2+) release causes myocyte depolarization. Underlying mechanism and threshold for triggered action potentials. Circ Res. 2000;87(9):774-780.
26.
Kumagai K., Nakashima H., Gondo N., Saku K.Antiarrhythmic effects of JTV-519, a novel cardioprotective drug, on atrial fibrillation/flutter in a canine sterile pericarditis model. J Cardiovasc Electrophysiol. 2003;14(8):880-884.
27.
Miyata A., Zipes DP, Hall S., Rubart M.Kb-R7943 prevents acute, atrial fibrillation-induced shortening of atrial refractoriness in anesthetized dogs. Circulation. 2002;106(11):1410-1419.
28.
Lee C., Visen NS, Dhalla NS, et al. Inhibitory profile of SEA0400 [2-[4-[(2,5-difluorophenyl)methoxy]phenoxy]-5-ethoxyaniline] assessed on the cardiac Na+-Ca2+ exchanger, NCX1.1. J Pharmacol Exp Ther. 2004;311(2):748-757.
29.
de Mello WC , Thormahlen D.Effect of tedisamil on cell communication, impulse propagation, and excitability of the failing heart. Eur J Pharmacol. 1999;372(3):241-246.
30.
Lin X., Zemlin C., Hennan JK, Petersen JS, Veenstra RDEnhancement of ventricular gap-junction coupling by rotigaptide. Cardiovasc Res. 2008;79(3):416-426.
31.
Guerra JM, Everett TH, Lee KW, Wilson E., Olgin JEEffects of the gap junction modifier rotigaptide (ZP123) on atrial conduction and vulnerability to atrial fibrillation. Circulation . 2006;114(2):110-118.
32.
Rossman EI, Liu K., Morgan GA, et al. The gap junction modifier, GAP-134 [(2S,4R)-1-(2-aminoacetyl)-4-benzamido-pyrrolidine2-carboxylic acid], improves conduction and reduces atrial fibrillation/flutter in the canine sterile pericarditis model. J Pharmacol Exp Ther.2009;329(3):1127-1133.
33.
Savelieva I. , John CAAtrial fibrillation and heart failure: natural history and pharmacological treatment. Europace. 2004;5(suppl 1):S5-S19.
34.
Lee KW, Everett TH, Rahmutula D., et al. Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation. 2006;114(16): 1703-1712.
35.
Savelieva I. , Camm J.Statins and polyunsaturated fatty acids for treatment of atrial fibrillation. Nat Clin Pract Cardiovasc Med. 2008;5(1):30-41.
36.
Katritsis DG , Panagiotakos DB, Karvouni E., et al. Comparison of effectiveness of carvedilol versus bisoprolol for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation. Am J Cardiol. 2003;92(9):1116-1119.
37.
Haghjoo M., Saravi M., Hashemi MJ, et al. Optimal beta-blocker for prevention of atrial fibrillation after on-pump coronary artery bypass graft surgery: carvedilol versus metoprolol . Heart Rhythm. 2007;4(9):1170-1174.
38.
Celik T., Iyisoy A., Jata B., Celik M., Gunay C., Isik E.Beta blockers for the prevention of atrial fibrillation after coronary artery bypass surgery: carvedilol versus metoprolol. Int J Cardiol.2009;135(3): 393-396.
39.
Haissaguerre M., Jais P., Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339(10):659-666.
40.
Fuster V., Ryden LE, Cannom DS, et al. ACC/AHA/ESC/ 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006;48(4):854-906.
41.
Oral H., Knight BP, Tada H., et al. Pulmonary vein isolation for paroxysmal and persistent atrial fibrillation. Circulation. 2002; 105(9):1077-1081.
42.
Pappone C., Rosanio S., Augello G., et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol. 2003;42(2):185-197.
43.
Oral H., Pappone C., Chugh A., et al. Circumferential pulmonary-vein ablation for chronic atrial fibrillation . N Engl J Med. 2006; 354(9):934-941.
44.
Vasamreddy CR , Dalal D., Eldadah Z., et al. Safety and efficacy of circumferential pulmonary vein catheter ablation of atrial fibrillation . Heart Rhythm. 2005;2(1):42-48.
45.
Smelley MP, Knight BPApproaches to catheter ablation of persistent atrial fibrillation . Heart Rhythm. 2009;6(8 suppl): S33-S38.
46.
Nademanee K. , Schwab MC, Kosar EM, et al. Clinical outcomes of catheter substrate ablation for high-risk patients with atrial fibrillation. J Am Coll Cardiol. 2008;51(8):843-849.
47.
Oral H., Chugh A., Good E., et al. Radiofrequency catheter ablation of chronic atrial fibrillation guided by complex electrograms. Circulation. 2007;115(20):2606-2612.
48.
Willems S., Klemm H., Rostock T., et al. Substrate modification combined with pulmonary vein isolation improves outcome of catheter ablation in patients with persistent atrial fibrillation: a prospective randomized comparison. Eur Heart J. 2006;27(23): 2871-2878.
49.
Elayi CS, Verma A., Di BL, Ching CK, Patel D., Barrett C., et al. Ablation for longstanding permanent atrial fibrillation: results from a randomized study comparing three different strategies. Heart Rhythm. 2008;5(12):1658-1664.
50.
Katritsis D. , Ellenbogen KA, Giazitzoglou E., et al. Clinical outcome of left atrial ablation for paroxysmal atrial fibrillation is related to the extent of radiofrequency ablation. J Interv Card Electrophysiol . 2008 ;22(1):31-37.
51.
Dixit S., Gerstenfeld EP, Ratcliffe SJ, et al. Single procedure efficacy of isolating all versus arrhythmogenic pulmonary veins on long-term control of atrial fibrillation: a prospective randomized study. Heart Rhythm. 2008;5(2):174-181.
52.
Cappato R., Calkins H., Chen SA, et al. Prevalence and causes of fatal outcome in catheter ablation of atrial fibrillation. J Am Coll Cardiol.2009;53(19):1798-1803.
53.
De PR, Cappato R., Curnis A., et al. Trans-septal catheterization in the electrophysiology laboratory: data from a multicenter survey spanning 12 years. J Am Coll Cardiol. 2006;47(5):1037-1042.
54.
Shah AN, Mittal S., Sichrovsky TC, et al. Long-term outcome following successful pulmonary vein isolation: pattern and prediction of very late recurrence. J Cardiovasc Electrophysiol. 2008; 19(7):661-667.
55.
Cappato R., Negroni S., Pecora D., et al. Prospective assessment of late conduction recurrence across radiofrequency lesions producing electrical disconnection at the pulmonary vein ostium in patients with atrial fibrillation. Circulation . 2003;108(13): 1599-1604.
56.
Neumann T., Erdogan A., Dill T., et al. Asymptomatic recurrences of atrial fibrillation after pulmonary vein isolation. Europace. 2006;8(7):495-498.
57.
Wazni OM, Marrouche NF, Martin DO, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA. 2005;293(21): 2634-2640.
58.
Stabile G., Bertaglia E., Senatore G., et al. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). Eur Heart J. 2006;27(2):216-221.
59.
Pappone C., Augello G., Sala S., et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. J Am Coll Cardiol. 2006;48(11):2340-2347.
60.
Jais P., Cauchemez B., Macle L., et al. Atrial fibrillation ablation versus antiarrhythmic drugs: a multicentre randomised trial (Abstract). Heart Rhythm Soc . 2006.
61.
Wilber DJ, Pappone C., Neuzil P., et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA.2010;303(4):333-340.
62.
Stabile G., De SA, Turco P., et al. Response to flecainide infusion predicts long-term success of hybrid pharmacologic and ablation therapy in patients with atrial fibrillation . J Am Coll Cardiol. 2001;37(6):1639-1644.
63.
Saksena S., Madan N.Hybrid therapy of atrial fibrillation: algorithms and outcome. J Interv Card Electrophysiol. 2003;9(2):235-247.
64.
Madan N., Saksena S.Long-term rhythm control of drug-refractory atrial fibrillation with ‘‘hybrid therapy’’ incorporating dual-site right atrial pacing, antiarrhythmic drugs, and right atrial ablation. Am J Cardiol. 2004;93(5):569-575.
65.
Kocheril AG , Calkins H., Sharma AD, Cher D., Stubbs HA, Block JEHybrid therapy with right atrial catheter ablation and previously ineffective antiarrhythmic drugs for the management of atrial fibrillation. J Interv Card Electrophysiol. 2005;12(3): 189-197.
66.
Camm AJ, Savelieva I.Rationale and patient selection for ‘‘hybrid’’ drug and device therapy in atrial and ventricular arrhythmias. J Interv Card Electrophysiol. 2003;9(2):207-214.
67.
Oral H., Knight BP, Ozaydin M., et al. Clinical significance of early recurrences of atrial fibrillation after pulmonary vein isolation. J Am Coll Cardiol. 2002;40(1):100-104.
68.
Turco P., De SA, La RV, et al. Antiarrhythmic drug therapy after radiofrequency catheter ablation in patients with atrial fibrillation. Pacing Clin Electrophysiol . 2007;30(suppl 1): S112-S115.
69.
Cappato R., Calkins H., Chen SA, Davies W., Iesaka Y., Kalman J., et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation. 2005.
70.
Camm AJSafety considerations in the pharmacological management of atrial fibrillation . Int J Cardiol. 2008;127(3): 299-306.
71.
Nanthakumar K., Plumb VJ, Epstein AE, Veenhuyzen GD, Link D., Kay GNResumption of electrical conduction in previously isolated pulmonary veins: rationale for a different strategy? Circulation. 2004;109(10):1226-1229.
72.
Verma A., Kilicaslan F., Pisano E., et al. Response of atrial fibrillation to pulmonary vein antrum isolation is directly related to resumption and delay of pulmonary vein conduction. Circulation. 2005;112(5):627-635.
73.
Jais P., Hocini M., Macle L., et al. Distinctive electrophysiological properties of pulmonary veins in patients with atrial fibrillation. Circulation. 2002;106(19):2479-2485.
74.
Tojo H., Kumagai K., Noguchi H., et al. Hybrid therapy with pilsicainide and pulmonary vein isolation for atrial fibrillation. Circ J. 2005;69(12):1503-1507.
75.
Kumagai K., Tojo H., Noguchi H., et al. Effects of the NA+ channel blocker pilsicainide on the electrophysiologic properties of pulmonary veins in patients with atrial fibrillation. J Cardiovasc Electrophysiol. 2004;15(12):1396-1401.
76.
Konings KT, Kirchhof CJ, Smeets JR, Wellens HJ, Penn OC, Allessie MAHigh-density mapping of electrically induced atrial fibrillation in humans . Circulation. 1994;89(4):1665-1680.
77.
Reithmann C. , Dorwarth U., Dugas M., et al. Risk factors for recurrence of atrial fibrillation in patients undergoing hybrid therapy for antiarrhythmic drug-induced atrial flutter. Eur Heart J. 2003;24(13):1264-1272.
78.
Turco P., De SA, La RV, et al. Long-term results of hybrid therapy in patients with atrial fibrillation who develop atrial flutter during flecainide infusion. Pacing Clin Electrophysiol. 2005;28(suppl 1):S124-S127.
79.
Ortiz J., Niwano S., Abe H., Rudy Y., Johnson NJ, Waldo ALMapping the conversion of atrial flutter to atrial fibrillation and atrial fibrillation to atrial flutter. Insights into mechanisms. Circ Res. 1994;74(5):882-894.
80.
Tai CT, Chiang CE, Lee SH, et al. Persistent atrial flutter in patients treated for atrial fibrillation with amiodarone and propafenone: electrophysiologic characteristics, radiofrequency catheter ablation, and risk prediction. J Cardiovasc Electrophysiol . 1999;10(9):1180-1187.
81.
Schumacher B., Jung W., Lewalter T., Vahlhaus C., Wolpert C., Luderitz B.Radiofrequency ablation of atrial flutter due to administration of class IC antiarrhythmic drugs for atrial fibrillation . Am J Cardiol. 1999;83(5):710-713.
82.
Lamas GA, Lee KL, Sweeney MO, et al. Ventricular pacing or dual-chamber pacing for sinus-node dysfunction . N Engl J Med. 2002;346(24):1854-1862.
83.
Silberbauer J., Sulke N.The role of pacing in rhythm control and management of atrial fibrillation. J Interv Card Electrophysiol . 2007;18(2):159-186.
84.
Nielsen JC, Kristensen L., Andersen HR, Mortensen PT, Pedersen OL, Pedersen AKA randomized comparison of atrial and dual-chamber pacing in 177 consecutive patients with sick sinus syndrome: echocardiographic and clinical outcome . J Am Coll Cardiol. 2003;42(4):614-623.
85.
Kerr CR, Connolly SJ, Abdollah H., et al. Canadian trial of physiological pacing: effects of physiological pacing during long-term follow-up. Circulation. 2004;109(3):357-362.
86.
Knight BP, Gersh BJ, Carlson MD, et al. Role of permanent pacing to prevent atrial fibrillation: science advisory from the American Heart Association Council on Clinical Cardiology (Subcommittee on Electrocardiography and Arrhythmias) and the Quality of Care and Outcomes Research Interdisciplinary Working Group, in collaboration with the Heart Rhythm Society. Circulation. 2005 ; 111(2):240-243.
Vos MA, Verduyn SC, Gorgels AP, Lipcsei GC, Wellens HJReproducible induction of early afterdepolarizations and torsade de pointes arrhythmias by d-sotalol and pacing in dogs with chronic atrioventricular block. Circulation. 1995;91(3): 864-872.
89.
Saksena S., Prakash A., Ziegler P., et al. Improved suppression of recurrent atrial fibrillation with dual-site right atrial pacing and antiarrhythmic drug therapy. J Am Coll Cardiol. 2002;40(6): 1140-1150.
90.
Prakash A., Saksena S., Krol RB, Filipecki A., Philip G.Catheter ablation of inducible atrial flutter, in combination with atrial pacing and antiarrhythmic drugs (’’hybrid therapy") improves rhythm control in patients with refractory atrial fibrillation. J Interv Card Electrophysiol. 2002;6(2):165-172.
91.
Khan MN, Jais P., Cummings J., et al. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med. 2008;359(17):1778-1785.
92.
Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation. 2002;106(3):331-336.
93.
Schmieder RE , Kjeldsen SE, Julius S.Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens. 2008;26(3):403-411.
94.
Disertori M. , Latini R., Barlera S., et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med . 2009;360(16): 1606-1617.
95.
Tveit A., Grundvold I., Olufsen M., et al. Candesartan in the prevention of relapsing atrial fibrillation . Int J Cardiol. 2007; 120(1):85-91.
96.
Cox JL, Schuessler RB, Cain ME, et al. Surgery for atrial fibrillation. Semin Thorac Cardiovasc Surg. 1989;1(1):67-73.
97.
Stulak JM, Dearani JA, Sundt TM III, et al. Superiority of cut-and-sew technique for the Cox maze procedure: comparison with radiofrequency ablation. J Thorac Cardiovasc Surg. 2007;133(4):1022-1027.
98.
Khargi K., Keyhan-Falsafi A., Hutten BA, Ramanna H., Lemke B., Deneke T.Surgical treatment of atrial fibrillation: a systematic review. Herzschrittmacherther Elektrophysiol. 2007;18(2):68-76.
99.
Matsutani N. , Takase B., Ozeki Y., Maehara T., Lee R.Minimally invasive cardiothoracic surgery for atrial fibrillation: a combined Japan-US experience . Circ J. 2008;72(3):434-436.
100.
Lim KT , Davis MJ, Powell A., et al. Ablate and pace strategy for atrial fibrillation: long-term outcome of AIRCRAFT trial . Europace . 2007;9(7):498-505.
101.
Tan ES , Rienstra M., Wiesfeld AC, Schoonderwoerd BA, Hobbel HH, Van GILong-term outcome of the atrioventricular node ablation and pacemaker implantation for symptomatic refractory atrial fibrillation. Europace. 2008;10(4):412-418.
